| Literature DB >> 26375281 |
Lu Mei1, Youcai Tang2, Ming Li3, Pingchang Yang4, Zhiqiang Liu5, Jieli Yuan3, Pengyuan Zheng6.
Abstract
Non-alcoholic fatty liver disease (NAFLD) has become a common liver disease in recent decades. No effective treatment is currently available. Probiotics and natural functional food may be promising therapeutic approaches to this disease. The present study aims to investigate the efficiency of the anthraquinone from Cassia obtusifolia L. (AC) together with cholesterol-lowering probiotics (P) to improve high-fat diet (HFD)-induced NAFLD in rat models and elucidate the underlying mechanism. Cholesterol-lowering probiotics were screened out by MRS-cholesterol broth with ammonium ferric sulfate method. Male Sprague-Dawley rats were fed with HFD and subsequently administered with AC and/or P. Lipid metabolism parameters and fat synthesis related genes in rat liver, as well as the diversity of gut microbiota were evaluated. The results demonstrated that, compared with the NAFLD rat, the serum lipid levels of treated rats were reduced effectively. Besides, cholesterol 7α-hydroxylase (CYP7A1), low density lipoprotein receptor (LDL-R) and farnesoid X receptor (FXR) were up-regulated while the expression of 3-hydroxy-3-methyl glutaryl coenzyme A reductase (HMGCR) was reduced. The expression of peroxisome proliferator activated receptor (PPAR)-α protein was significantly increased while the expression of PPAR-γ and sterol regulatory element binding protein-1c (SREBP-1c) was down-regulated. In addition, compared with HFD group, in AC, P and AC+P group, the expression of intestinal tight-junction protein occludin and zonula occluden-1 (ZO-1) were up-regulated. Furthermore, altered gut microbiota diversity after the treatment of probiotics and AC were analysed. The combination of cholesterol-lowering probiotics and AC possesses a therapeutic effect on NAFLD in rats by up-regulating CYP7A1, LDL-R, FXR mRNA and PPAR-α protein produced in the process of fat metabolism while down-regulating the expression of HMGCR, PPAR-γ and SREBP-1c, and through normalizing the intestinal dysbiosis and improving the intestinal mucosal barrier function.Entities:
Mesh:
Substances:
Year: 2015 PMID: 26375281 PMCID: PMC4573521 DOI: 10.1371/journal.pone.0138078
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
The abilities of candidate strains to reduce cholesterol.
| Strains | Strains in different media of cholesterol degradation rate (48h) | |
|---|---|---|
| MRS-CHOL(%) | MRS-CHOL+TAC(%) | |
|
| 55.87±0.26 a | 58.62±0.45 a |
|
| 55.48±0.40b | 65.21±0.27 a |
|
| 56.04±0.35b | 62.21±0.33 a |
|
| 56.52±0.27 a | 61.97±0.31 a |
|
| 55.11±0.23a | 56.97±0.41 a |
|
| 59.91±0.29 a | 56.53±0.25 a |
|
| 57.71±0.34b | 68.69±0.47 a |
MRS-CHOL, MRS broth at a final concentration of cholesterol was 0.1mg/ml. Results are expressed as mean ± SD (n = 7). Means within a row with different superscript letter significantly different (P <0.05)
Serum TC, TG, HDL, LDL, and FFA concentrations in SD rats fed the experimental diets.
| Lipid profile | ND | HFD | HFD+AC | HFD+P | HFD+AC+P |
|---|---|---|---|---|---|
|
| 127.95±4.52d | 223.12±5.61a | 179.88±4.29b | 160.96±6.87bc | 150.62±5.63cd |
|
| 75.15±4.28d | 136.86±5.64a | 111.93±4.22b | 120.29±5.14b | 102.45±4.39c |
|
| 57.33±3.67d | 156.65±5.96a | 121.73±3.89b | 112.06±3.91b | 89.93±3.57c |
|
| 76.07±3.05a | 49.01±3.12d | 53.96±3.06c | 59.97±4.79b | 62.41±2.26b |
|
| 29.42±3.58c | 60.94±4.28a | 46.85±3.91b | 42.41±3.14b | 37.37±3.87bc |
|
| 0.75±0.34e | 3.20±0.32a | 2.27±0.15b | 1.88±0.29c | 1.44±0.11d |
|
| 1.72±0.21d | 4.49±0.41a | 3.31±0.49b | 2.72±0.19c | 2.39±0.23c |
TC, total cholesterol; TG, total triacylglycerol; LDL, low-density lipoprotein; HDL, high-density lipoprotein; FFA, free fatty acid.
Results are expressed as mean±SD, n = 6. Means within a row with different superscript letters are significantly different (P<0.05).